Appropriate Castration with Luteinising Hormone Releasing Hormone (LHRH) Agonists: What is the Optimal Level of Testosterone?  B. Tombal  European Urology Supplements  Volume 4, Issue 5, Pages 14-19 (July 2005) DOI: 10.1016/j.eursup.2005.04.004 Copyright © 2005 Elsevier B.V. Terms and Conditions

Fig. 1 The percentage of patients that do not reach testosterone castration levels below 50ng/dL is negligible. Setting the castration threshold on 20ng/dL is more reliable, as seen that more patients do not reach this threshold [16–18,29]. 1, 3M: depot formulation of respectively 1 or 3 months; L: leuprolide. European Urology Supplements 2005 4, 14-19DOI: (10.1016/j.eursup.2005.04.004) Copyright © 2005 Elsevier B.V. Terms and Conditions

Fig. 2 About 7% of patients receiving LHRH agonists will have a breakthrough response, if the castration level is set at 50ng/dL [21–23]. 3M: 3 month depot formulation; G: goserelin; L: leuprolide. European Urology Supplements 2005 4, 14-19DOI: (10.1016/j.eursup.2005.04.004) Copyright © 2005 Elsevier B.V. Terms and Conditions

Fig. 3 If the castration level is set at 50ng/dL, about 6% of patients will have an acute-on-chronic response [6,21,24]. 1, 3M: depot formulation of respectively 1 or 3 months; G: goserelin; L: leuprolide. European Urology Supplements 2005 4, 14-19DOI: (10.1016/j.eursup.2005.04.004) Copyright © 2005 Elsevier B.V. Terms and Conditions

Fig. 4 Median serum testosterone level remains below 20ng/dL for up to 6 months, after the administration of a 3-month depot LHRH agonist [26]. European Urology Supplements 2005 4, 14-19DOI: (10.1016/j.eursup.2005.04.004) Copyright © 2005 Elsevier B.V. Terms and Conditions